3. Introduction
ds- DNA virus- Papillomavirus
>100 HPV types
Needs keratinocytes- “Skin virus”
Skin or
Mucous membranes- about 40 genital HPV types
Of which, 15-18 genital types associated with cancer
8. Genital HPV is
Problem Statement
EVERYWHERE!
Human papillomavirus (HPV) is an extremely common
STD, with an estimated 80 percent of sexually active
people contracting it at some point in their lives;
Incidence: 14 million new infections occur yearly.
Prevalence: About 79 million people (both men and
women) are thought to have an active HPV infection at
any given time.
SKIN contact, not body fluids
9. In India
In India, Ca Cervix is the No 1 cancer among women,
with an incidence of 27.0 per 100,000 women and an
age standardized mortality rate as high as 45.2 per
100,000 women (2008)
10. Epidemiologic Relationships of
HPV
Well Established:
Cervical Dysplasia and Cancer
Genital Warts
Recurrent Respiratory Papillomatosis
As well as:
Anogenital cancers (vulvar, penile, vaginal)
Head and Neck Cancer (esophagus, pharynx)
11. In the West, 30% of oral carcinoma is related to HPV. It
is commonly seen in ages 20- 39 years
The risk of contracting oropharayngeal cancer (cancer of
the tonsils, back of throat or base of the tongue)
heightens 3.4 times with 6 or more oral sex partners
The survival rate for those with HPV-positive head and
neck tumors is 85% in non-smoking people. The survival
rate drops down to 45-50% for smokers.
12. Global Perspective on Cervical
Cancer
2nd most common cancer in women
The cancer that kills more women on a world wide basis every
year
>250,000 women die each year world wide
One woman dies every two minutes from cervical cancer
Leading cause of death from cancer in developing countries
13. HPV Transmission
Sexual- Intercourse
•
Genital (non-penetrative), oral, digital contact (skin to skin
contact)
•
Condoms help, but not completely protective
Non-sexual
•
Mother to newborn (vertical transmission - rare)
•
Possibly via fomites (underwear, equipment)
•
Can be seen in virgins (rare)
SKIN contact, not body fluids
16. Most HPV Infections Resolve
HPV “Clearance”
•
80- 90% of infections will resolve in 2 years
•
Average duration of infection 9- 13 months
•
Unclear if virus is eradicated or latent
HPV “Persistence”
•
10- 20% of infections persist
• Major risk factor for developing cancer
•
Risk factors for persistence not well understood
* Clearance and persistence is age related
17. Age-related Trends in HPV
Infection in Women
Mean Prevalence
2.5
2
1.5
Oncogenic
Non-oncogenic
1
0.5
0
<25 25- 3534 44
45- 55- >65
54 64
Age group
18. Age Specific Rates of HPV-Related
Genital Cancers in the U.S.
20
Cervix
Vulva
15
Penis
10
Anus
Female
Vagina
5
Anus Male
Age Range in Years
85+
80-84
75-79
70-74
65-69
60-64
55-59
50-54
45-49
40-44
35-39
30-34
25-29
20-24
0
15-19
Incidence per 100,000
25
19. HPV During Adolescence
Risk of Genital HPV Infection from Time of First Sexual Intercourse
1
Cumulative Incidence of HPV
0.9
0.8
0.7
~50%
Cumulative
Incidence
0.6
0.5
0.4
0.3
0.2
0.1
0
0
4
8
12
16
20
24
28
32
36
40
44
Months Since First Intercourse
48
52
56
60
20. HPV in Adolescence
Of all new HPV infections, 74% occur in the 1524 year old age group
Adolescents particularly vulnerable
• Biological:
• Immune immaturity
• Large transformation zone of cervix
• Behavioral (In the West)
21. Why are Adolescent Women More
Susceptible to HPV?
Large transformation zone
22. The New ACOG Screening Guidelines
(Oct 2012)
Pap tests should begin at age 21, regardless of sexual history
Pap testing should not be done for most women more often
than every 3 years- NO traditional "annual Pap" regimen,
but those with abnormal Paps will be tested more often
(yearly)
Rather than using a Pap test alone, HPV/Pap co-testing is
now the preferred method of screening women age 30 and
over.
Such co-testing should only occur once every 5 years with
women who have normal test results
23. HPV testing should NOT be done in women under age 30 other
than as follow-up to unclear Pap test results
Cervical cancer screening can end for most women at age
65, provided she has no history of cervical pre-cancer or
cancer, and has had at least three consecutive, normal Pap tests (or
two normal HPV tests) within the last 10 years.
Women at greater risk for cervical cancer (e.g., those with a history
of cervical pre- cancer or cancer and those who are HIV-positive or
otherwise have weakened immune systems) may require screening
more frequently
24.
25. HPV VLP Vaccines
Bivalent (Cervarix) :
{0, 1, 6}
HPV 16
HPV 18
70% of Cervical Ca
ASO4 Adjuvant (MPL + Alum)
Quadrivalent (Gardasil) : HPV 16
{0, 2, 6}
HPV 18
70% of Cervical Ca
HPV 6
HPV 11
90% of Genital Warts
Aluminum as adjuvant
IM Injections at 0, 1 or 2, and 6 months
26. Vaccine Schedule
Dosing schedules with the vaccines are at 0, 1 to 2
months, and 6 months.
Minimum intervals are 4 weeks between doses 1 and
2, 12 weeks between doses 2 and 3, and 24 weeks
between the first and third doses.
It is likely that variations in scheduled doses do not
seriously impair the vaccines’ effectiveness; therefore, the
vaccine series should not be restarted if the schedule is
interrupted.
27.
28. Assembly of HPV VLPs
Structural model of papillomavirus VLP*
VLP
(~20,000 kD)
L1 Protein
(55–57 kD)
L1 Capsomere
(~280 kD)
5 x L1
VLP = Virus- like particle
72
Capsomeres
36. SPECIAL SITUATIONS
Equivocal or abnormal Pap test OK
Positive HPV test OK
Genital warts OK
Immunosuppression OK
Lactating women OK
37. Precautions and Contradictions
Moderate or severe acute illnesses: should be
deferred until after the illness improves
History of hypersensitivity or severe allergic
reaction to yeast or to any vaccine component
Pregnancy
38. Key Issues Remaining
Pap smear screening recommendations will NOT change.
Only HPV 16/18 are included in the vaccine; 13 other types
implicated in Cervical Cancer
Should older women (>26 years of age) be vaccinated?
YES, older women who are not with abnormal Pap, and not
currently HPV infected, can be vaccinated
39. HPV Among Boys
When the percentage of girls getting vaccinated are in the 30 to 40
percent range, vaccinating boys is suggested to have a substantial
enhancing impact on trying to protect those girls who are not
vaccinated.
This would provide "herd immunity." Boys don't get cervical cancer,
but they can transmit HPV. So vaccinating boys would reduce the
amount of HPV circulating in the population
The reason for moving away from the annual Pap is evidence shows little gain in testing more often, but potential harm of “over screening” such as follow-up exams (like colposcopy/biopsy) and treatment to the cervix, especially with women of child-bearing age.